Cargando…
Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients
Venous thromboembolism (VTE) is a common cause of morbidity and mortality in patients with cancer. Compared with the general population, cancer patients with VTE have higher rates of both VTE recurrence and bleeding. While low molecular weight heparin (LMWH) has been the mainstay of treatment for ca...
Autores principales: | Song, Andrew B, Rosovsky, Rachel P, Connors, Jean M, Al-Samkari, Hanny |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593743/ https://www.ncbi.nlm.nih.gov/pubmed/31417269 http://dx.doi.org/10.2147/VHRM.S132556 |
Ejemplares similares
-
The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis
por: Al-Samkari, Hanny, et al.
Publicado: (2018) -
Physician perceptions and use of reduced‐dose direct oral anticoagulants for extended phase venous thromboembolism treatment
por: Groat, Danielle, et al.
Publicado: (2022) -
Direct oral anticoagulants and venous thromboembolism
por: Franchini, Massimo, et al.
Publicado: (2016) -
Venous Thromboembolism: A Survey of Oral Anticoagulant Preferences in the
Treatment of Challenging Patient Populations
por: Moyer, Genevieve Claire, et al.
Publicado: (2018) -
Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan
por: Nakamura, Mashio, et al.
Publicado: (2017)